Damian Kovalovsky, Ph.D.

Dr. Kovalovsky directs the Branch's T-Cell Engineering Facility, providing support for the pre-clinical development of new T-cell therapies and analysis of several research endpoints related to the immune response in ongoing immunotherapy clinical trials.
1) hematopoietic differentiation, 2) T-cell response, 3) immunology
Contact Info
Center for Cancer Research
National Cancer Institute
Building 10, Room 12C217
Bethesda, MD 20892
Ph: 240-858-3242
Fax: 240-541-4566
damian.kovalovsky@nih.gov
The T-Cell Engineering Facility provides support for the development and implementation of novel immunotherapies as well as the analysis of immune endpoints in ongoing clinical trials.
Selected Key Publications
- Oncotarget. 7: 58768-58778, 2016. [ Journal Article ]
- J Immunol. 197: 1199-211, 2016. [ Journal Article ]
- J Immunol. 195: 4273-81, 2015. [ Journal Article ]
- J Immunol. 184: 6746-55, 2010. [ Journal Article ]
- Nat Immunol. 9: 1055-64, 2008. [ Journal Article ]
Dr. Kovalovsky received his Ph.D from the University of Buenos Aires, Argentina. He obtained postdoctoral training at the Molecular Oncology Research Institute, Tufts-New England Medical Center and at Memorial Sloan Kettering Cancer Center, where he studied the mechanisms of negative selection of thymocytes as well as the differentiation of iNKT cells. Before joining the Experimental Transplantation and Immunology Branch, he was an investigator in the Experimental Immunology Branch where he studied the transcription factors controlling the differentiation of hematopoietic progenitors and T-cells.
Name | Position |
---|---|
Samantha Simon Ph.D. | Biologist (Contr.) |
Elisaveta Voynova Ph.D. | Scientist (Contr.) |